Press Releases | BlossomHill Therapeutics

BlossomHill Therapeutics Doses Patients in the First Cohort of the Phase 1/2 SOLARA Clinical Trial of BH-30643 for EGFR- and HER2-Mutated Non-Small Cell Lung Cancer

January 22, 2025/in Press Releases/by eallison

BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President

January 3, 2025/in Press Releases/by eallison

*3a1l5p*_gcl_au*NjE4NTg5MDEyLjE3MzYxNjgxODA.*_ga*MTgyMDc2MDE4MC4xNzM2MTY4MTgw*_ga_ZQWF70T3FK*MTczNjE2ODE4MC4xLjEuMTczNjE2ODQzNi4zNi4wLjA

BlossomHill Therapeutics Closes $100M Series B Financing

May 31, 2024/in Press Releases/by eallison

BlossomHill Therapeutics Chief Executive Officer Jingrong Jean Cui, Ph.D., Elected to the National Academy of Engineering

May 31, 2024/in Press Releases/by eallison

BlossomHill Therapeutics Closes $71M Series A Financing

May 31, 2024/in Press Releases/by eallison